Search Results for: Metastasized

March 13, 2019March 13, 2019

Methylation analysis highlights novel prognostic criteria in human-metastasized melanoma.

Melanoma Literature

Publication date: Mar 12, 2019 Melanoma accounts for 90% of the deaths associated with cutaneous neoplasms, and the 5-year survival rate of patients with the advanced stage is about 20%. ... Read more

March 13, 2019March 13, 2019

Methylation analysis highlights novel prognostic criteria in human-metastasized melanoma.

Melanoma Literature

October 12, 2018October 12, 2018

[Immunotherapy for locally advanced and metastasized bladder cancer].

Melanoma Literature

Publication date: Oct 09, 2018 Urothelial carcinoma of the bladder is difficult to treat in advanced and metastatic stages. Several factors play a role: age, multimorbidity including impaired renal function ... Read more

June 21, 2018June 21, 2018

Melanoma Metastasized to the Brain and Steroids

Melanoma News

Publication date: Jun 20, 2018 This clinical trial is to clarify whether treatment with a checkpoint inhibitor alone (pembrolizumab) or two in combination (ipilimumab and nivolumab), results in clinical benefit ... Read more

December 4, 2019December 4, 2019

Cutaneous Metastases from Solid Neoplasms in the 21 Century: A Retrospective Study from a Portuguese Tertiary Care Center.

Melanoma Literature

Publication date: Dec 02, 2019 Cutaneous metastases account for 2% of all skin cancers and are usually associated with widespread disease. The main purpose of this retrospective study was to ... Read more

November 15, 2019November 15, 2019

Cardiac metastases in melanoma

Melanoma Media

Publication date: Nov 14, 2019 Concepts Keywords Arjun Skin cancers treat Ascetic Cancers Asylum Tumor Band Aid Korea Tumors Basement Membrane Borders melanoma Bowling Melanoma cancer Cancer Stage metastatic melanoma ... Read more

October 23, 2019October 23, 2019

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma

Melanoma News

Publication date: Oct 21, 2019 DONIMI is a phase 1b trial testing the combination of domatinostat + nivolumab or nivolumab monotherapy in IFN-gamma signature high patients and of domatinostat + ... Read more

July 28, 2019July 28, 2019

Immunotherapies for the Treatment of Uveal Melanoma-History and Future.

Melanoma Literature

Publication date: Jul 24, 2019 Uveal melanoma is the most common primary intraocular malignancy among adults. It is, nevertheless, a rare disease, with an incidence of approximately one case per ... Read more

July 23, 2019July 23, 2019

How the pharmaceutical companies, Congress and the DEA made the opioid epidemic a billion-dollar industry

Opioids News

Publication date: Jul 23, 2019 During the six-year period, drug manufacturers and distributors flooded the country with 76 billion prescription pain pills, fueling an opioid epidemic that now kills 50,000 ... Read more

July 14, 2019July 14, 2019

Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study.

Melanoma Literature

Publication date: Jul 12, 2019 Metastasized or unresectable melanoma has been the first malignant tumor to be successfully treated with checkpoint inhibitors. Nevertheless, about 40-50% of the patients do not ... Read more